Abbott: Neoplasms trials

The registry lists 14 Neoplasms studies with Abbott as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 1Phase 3 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Falcon Real World Evidence RegistryRecruitingNCT06589310
• Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and CancerCompletedNCT01397747Results posted
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic MalignanciesTerminatedNCT03727009
• Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung CancerCompletedNCT03633006
• Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)CompletedNCT02503696
• Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract CancersTerminatedNCT02503631
• Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel DiseaseCompletedNCT01819766
• Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation TestingCompletedNCT01600209
• A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsTerminatedNCT01506934Phase 1
• Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT01401933Phase 1
• A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.TerminatedNCT01286974Phase 1
• Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development StudiesCompletedNCT01260168
• To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid TumorsCompletedNCT01193140Phase 2
• Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT01009593Phase 3